Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy

Clinical and Experimental Allergy

Volumn 45, Issue 10, 2015, Pages 1579-1589

  Korosec P ^a   Ziberna K ^a   Silar M ^a   Dezman M ^a   Celesnik Smodis N ^a   Rijavec, M ^a   Kopac P ^a   Erzen R ^a   Lalek, N ^a   Bajrovic N ^a   Kosnik M ^a   Zidarn, M ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

Adverse systemic reactions; Basophils; CD63; Honeybee venom allergy; IgE; Immunotherapy; Risk factors

Indexed keywords

ALLERGEN; BEE VENOM ALLERGEN EXTRACT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD63 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN E; TRYPTASE; UNCLASSIFIED DRUG; BEE VENOM;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BASOPHIL; BEE STING; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; DISEASE EXACERBATION; DISEASE SEVERITY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKIN MANIFESTATION; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; HYPERSENSITIVITY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD63; BASOPHILS; BEE VENOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; MALE; MIDDLE AGED;

EID: 84941622336     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12582     Document Type: Article

References (34)

1. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study III: safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86: 775-80.
2. Mueller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-35.
3. Mosbech H, Mueller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-10.
4. Rueff F, Przybilla B, Bilo MB et al. Predictors of side effects during the build-up phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105-11, e5.
5. Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991; 88:328-38.
6. Korošec P, Eržen R, Šilar M, Bajrović N, Kopač P, Košnik M. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy 2009; 39:1730-7.
7. Korošec P, Šilar M, Eržen R et al. Clinical routine utility of basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on individuals with negative venom-specific IgE antibodies. Int Arch Allergy Immunol 2013; 161:363-8.
8. Eberlein B, Krischan L, Darsow U, Ollert M, Ring J. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2012; 130:155-61.
9. Eržen R, Košnik M, Silar M, Korošec P. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012; 67:822-30.
10. Žitnik SE, Vesel T, Avčin T, Šilar M, Košnik M, Korošec P. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr Allergy Immunol 2012; 23:166-72.
11. Košnik M, Šilar M, Bajrović N, Mušič E, Korošec P. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 2005; 60:1401-6.
12. Eberlein-König B, Schmidt-Leidescher C, Behrendt H, Ring J. Predicting side-effects in venom immunotherapy by basophil activation? Allergy 2006; 61:897.
13. Čelesnik N, Vesel T, Rijavec M et al. Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response. Allergy 2012; 67:1594-600.
14. Bonifazi F, Jutel M, Bilo' BM, Birnbaum J, Muller U, EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
15. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:569-74, 574.e1-574.e7.
16. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis: a statement of the World Allergy Organization. Allergy 2008; 63:1061-70.
17. Ring J, Meßmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466-9.
18. Čelesnik Smodiš N, Silar M, Eržen R, Rijavec M, Košnik M, Korošec P. Down-regulation of FcεRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization. PLoS ONE 2014; 9:e94762.
19. Santos AF, Du Toit G, Douiri A et al. Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut. J Allergy Clin Immunol 2015; 135:179-86.
20. Johansson SG, Nopp A, van Hage M et al. Passive IgE-sensitization by blood transfusion. Allergy 2005; 60:1192-9.
21. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80:27-38.
22. Heinze G, Ploner M, Dunkler D, Southworth H. Logistf: Firth's bias reduced logistic regression. R package version 1.21. Vienna: Medical University of Vienna, 2013.
23. Nopp A, Johansson SG, Ankerst J et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006; 61:298-302.
24. Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009; 64:811-4.
25. Lalek N, Košnik M, Šilar M, Korošec P. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40:1186-93.
26. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003; 33:58-64.
27. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006; 16:79-85.
28. Köhler J, Blank S, Müller S et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol 2014; 133:1383-9.
29. Korošec P, Valenta R, Mittermann I et al. Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy. J Allergy Clin Immunol 2011; 128:671-3.
30. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19:225-9.
31. Eckman JA, Sterba PM, Kelly D et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010; 125:889-895.e7.
32. Rueff F, Przybilla B, Bilo MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-54.
33. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-45.
34. Peternelj A, Silar M, Erzen R, Kosnik M, Korosec P. Basophil sensitivity in patients not responding to venom immunotherapy. Int Arch Allergy Immunol 2008; 146:248-54.